Insider · CIK 0001221590
Jean Jacques Bienaime
Files at INCY (INCYTE CORP), IMNM (Immunome Inc.), ASND (Ascendis Pharma A/S), KROS (Keros Therapeutics, Inc.). First filing Mar 25, 2025, latest Jun 3, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IMNM: Immunome Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | IMNMbuy Immunome Inc. | $47k 5,000 shares | +16% | +67% from low-42% from high | |
| 48Moderate | Immunome Inc. | $61k 7,800 shares | +33% | - | |
| 43Moderate | Immunome Inc. | $57k 7,000 shares | +42% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 14, 2026 | ASND Ascendis Pharma A/S | DDisposition to issuer Warrantsderivative | -9,160 | - | - | 0 | 14 d ago |
| Apr 14, 2026 | ASND Ascendis Pharma A/S | AGrant or award Warrantsderivative | +9,160 | - | - | 9,160 | 14 d ago |
| Jun 10, 2025 | IMNM Immunome Inc. | AGrant or award Director Stock Option (right to buy)derivative | +18,864 | $0.00 | $0 | 18,864 | Jun 12, 2025 |
| Jun 10, 2025 | INCY INCYTE CORP | AGrant or award Common Stock | +2,518 | $0.00 | $0 | 20,841 | Jun 12, 2025 |
| Jun 10, 2025 | INCY INCYTE CORP | AGrant or award Non Qualfied Stock Option (right to buy)derivative | +9,216 | $0.00 | $0 | 9,216 | Jun 12, 2025 |
| Jun 4, 2025 | KROS Keros Therapeutics, Inc. | AGrant or award Common Stock | +5,250 | $0.00 | $0 | 5,450 | Jun 6, 2025 |
| Jun 4, 2025 | KROS Keros Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,500 | $0.00 | $0 | 10,500 | Jun 6, 2025 |
| Jun 3, 2025 | IMNM Immunome Inc. | POpen-market purchase Common Stock | +5,000 | $9.38 | $47k | 36,415 | Jun 3, 2025 |
| Mar 25, 2025 | IMNM Immunome Inc. | POpen-market purchase Common Stock | +7,800 | $7.78 | $61k | 31,415 | Mar 26, 2025 |
| Mar 24, 2025 | IMNM Immunome Inc. | POpen-market purchase Common Stock | +7,000 | $8.21 | $57k | 23,615 | Mar 25, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.